NCT07313579Recruiting
Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer
Observational Prospective Cohort Study on Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer
Source: ClinicalTrials.gov · Last updated 13 Jan 2026
Brief summary (registry, in English)
The study investigates the outcomes of hyperthermic intraperitoneal chemoperfusion (HIPEC) in combination with curative-intent gastrectomy in resectable locally-advanced and limited-metastatic (low peritoneal cancer index) gastric cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 8 Dec 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 1 Dec 2030
- Lead sponsor
- Ukrainian Society of Clinical Oncology
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07313579
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Dec 2025 to the primary completion date, 1 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant malignancy
Other illness
- Mitomycin and/or Cisplatin hypersensitivity
- Uncontrollable chronic diseases
- Patients with coexisting malignancy other than basal cell carcinoma of the skin within the last five years.
- History of allergic reactions associated with cisplatin and Mitomycin C
- Patients with psychiatric illness/social situations with impaired compliance
Other
- Pregnancy/breastfeeding
- ECOG status 2-4
- Presence of metastases other than regional or peritoneal (such as liver, lungs, bone, brain, distant lymph nodes)
- •Refusal to participate
Who the study is looking for
- Age 18-80
- Hystologicaly proven gastric adenocarcinoma
- ECOG status 0-1
- Written consent to participate in the study
- Medically and technically operable gastric tumor
- Only T4a or T4b tumours with any peritoneal cytology status
- Cytologically positive peritoneal washings (cyt+) with any T and N criteria
- Adequate haemopoetic, renal and hepatic function (Hb \> 120, PLT \> 150\*10\^9/l, ALT \< 60, AST \<40, total bilirubin \< 21 µmol/l, Creatinine clearance (male - 90-140, female - 80-130 ml/min)
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cancer Institute (NCI) Coordinator of this site? Confirm its status | Kyiv | Ukraine | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.